Benzinga | Dec 16, 2021 06:04AM EST

SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro

FDA laboratory testing confirms SAB-185 neutralizes Omicron

and other variants of concern with in vitro pseudovirus model

SAB's targeted, highly potent and fully-human polyclonal antibodies continue

to show broad neutralization to viral variants

SAB-185 currently being evaluated in NIH-sponsored Phase 3 COVID trial